We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura.
American Journal of Health-system Pharmacy : AJHP 2009 January 16
PURPOSE: The incidence and epidemiology, the pathogenesis, the clinical symptoms and diagnosis and the first-line therapies for the management of chronic immune thrombocytopenic purpura (ITP) are discussed. In addition, the recommendations of two expert panels for the management of ITP are summarized.
SUMMARY: The diagnosis and management of chronic ITP are a challenge to the clinician caring for patients with this disease. Because the pathophysiology of ITP is not completely understood, a variety of medical interventions have been utilized in the management of ITP. National guidelines have established that oral corticosteroids are considered to be first-line therapy for chronic ITP. In addition, the use of intravenous immune globulin has demonstrated efficacy in the treatment of the disease. Intravenous methylprednisolone, anti-D immunoglobulin, and splenectomy have been utilized in recurrent or refractory cases. The use of other immunosuppressant medications and newer thrombopoietin stimulating agents may offer additional treatment options, as presented in the subsequent article.
CONCLUSION: The initial management of chronic ITP should consist of the use of oral corticosteroids according to national guidelines. In the absence of a response to this first-line therapy, intravenous gamma globulin, intravenous methylprednisolone, anti-D immunoglobulin, or splenectomy may be considered. These treatments may also be utilized to manage recurrent cases of ITP, prior to consideration of second-line therapies.
SUMMARY: The diagnosis and management of chronic ITP are a challenge to the clinician caring for patients with this disease. Because the pathophysiology of ITP is not completely understood, a variety of medical interventions have been utilized in the management of ITP. National guidelines have established that oral corticosteroids are considered to be first-line therapy for chronic ITP. In addition, the use of intravenous immune globulin has demonstrated efficacy in the treatment of the disease. Intravenous methylprednisolone, anti-D immunoglobulin, and splenectomy have been utilized in recurrent or refractory cases. The use of other immunosuppressant medications and newer thrombopoietin stimulating agents may offer additional treatment options, as presented in the subsequent article.
CONCLUSION: The initial management of chronic ITP should consist of the use of oral corticosteroids according to national guidelines. In the absence of a response to this first-line therapy, intravenous gamma globulin, intravenous methylprednisolone, anti-D immunoglobulin, or splenectomy may be considered. These treatments may also be utilized to manage recurrent cases of ITP, prior to consideration of second-line therapies.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app